For the Inventor, By the Inventor

Enter assignee name

Galderma Research & Development

USPTO Granted Patents = 222

% Expired Patents = 52.3

CIPO Patents = 10

EPO Patents = 142

Forward Citations = 465

Loading Chart...

Loading Chart...

153 inventors (with patents filed for the assignee):

Laurence Clary (35 out of 37 patents)

Jean-Guy Boiteau (25 out of 34 patents)

Claire Mallard (19 out of 33 patents)

4. Claire Bouix-Peter (18 out of 18 patents)

5. Jean-Claude Pascal (17 out of 24 patents)

6. Etienne Thoreau (17 out of 19 patents)

7. Michael Graeber (17 out of 30 patents)

8. Thibaud Biadatti (16 out of 19 patents)

9. Michel Rivier (15 out of 16 patents)

10. Branislav Musicki (14 out of 17 patents)

11. Pascal Collette (14 out of 14 patents)

12. Janusz Czernielewski (13 out of 15 patents)

13. Jerôme Aubert (12 out of 12 patents)

14. Jean-Michel Bernardon (12 out of 86 patents)

15. Laurent Chantalat (10 out of 18 patents)

Core Competencies:

Photodynamic Treatment

mTOR Inhibitors

Chemical Foam

Retinoid Compounds

Dermatological Composition

Acne Treatment

Nanoparticles

Lipid Microcapsules

Skin Disorders

Hyaluronic Acid

Inflammatory Diseases

Cosmetic Applications

222 patents: Sort by Forward Citations

1. 11731973 - Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors (2023-08-22),

2. 11730814 - Pulse photodynamic treatment of photodamaged skin (2023-08-22),

3. 11518767 - MTOR inhibitor compounds (2022-12-06),

4. 11375946 - UV device for smartphone-based evaluation of skin conditions (2022-07-05),

5. 11278548 - Methods and compositions for reducing side effects in chemotherapeutic treatments (2022-03-22),

6. 11235010 - Composition containing lactic acid bacteria and its use to treat atopic dermatitis (2022-02-01),

7. 11234931 - No-rinse chemical foam containing brimonidine, and use thereof in the treatment of rosacea (2022-02-01),

8. 11214655 - Method of crosslinking glycosaminoglycans (2022-01-04),

9. 11197831 - Compositions comprising at least one dispersed active principle and lipid microcapsules (2021-12-14),

10. 11162831 - Device for packaging and dispensing a product, notably a pharmaceutical or cosmetic product (2021-11-02),

11. 11160812 - No-rinse chemical foam containing clobetasol propionate, and use thereof in the treatment of psoriasis (2021-11-02),

12. 11020348 - No-rinse chemical foam containing trifarotene, and use thereof in the treatment of ichthyosis (2021-06-01),

13. 11020347 - No-rinse chemical foam containing trifarotene, and use thereof in the treatment of acne (2021-06-01),

14. 10995052 - Biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof (2021-05-04),

15. 10987307 - No-rinse chemical foam comprising ivermectin (2021-04-27),

Galderma Research & Development, headquartered in Biot, France, specializes in innovative dermatological treatments. The company focuses on developing advanced solutions for skin conditions, leveraging technologies such as photodynamic treatment, mTOR inhibitors, and retinoid compounds. Galderma is committed to enhancing patient care through its research in chemical foams, acne treatments, and the use of nanoparticles and lipid microcapsules, aiming to provide effective and safe dermatological compositions for diverse skin health needs.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Galderma Research & Development

222 Patents

#2 in Biot

#122 in France

#3,845 in the World

Galderma Research & Development

Forward Citations = 465

153 inventors:

Laurence Clary (35 out of 37 patents)

Jean-Guy Boiteau (25 out of 34 patents)

Claire Mallard (19 out of 33 patents)

4. Claire Bouix-Peter (18 out of 18 patents)

5. Jean-Claude Pascal (17 out of 24 patents)

Please report any incorrect information to [email protected]

Loading…